In a 61-year-old patient with an eGFR of approximately 50 mL/min/1.73 m² and unknown proteinuria, what is the appropriate stepwise antihypertensive therapy using amlodipine, hydrochlorothiazide, losartan, or metoprolol?

Antihypertensive Therapy Strategy Without Known Proteinuria Status

In a 61-year-old patient with eGFR ~50 mL/min/1.73 m² and unknown proteinuria status, start with losartan 50 mg daily as first-line therapy, given the reasonable assumption that proteinuria may be present in CKD stage 3, and add hydrochlorothiazide 12.5 mg if blood pressure remains uncontrolled.

Rationale for Initial Therapy Selection

Why Losartan First?

The KDIGO 2021 guidelines provide clear direction here. While RAS inhibitors (ACE inhibitors or ARBs like losartan) are strongly recommended for patients with known moderate-to-severe albuminuria 1, the guidelines also state it "may be reasonable to treat people with high BP, CKD, and no albuminuria, with or without diabetes, with RASi" 1. Given that:

• Proteinuria is common in CKD stage 3 (eGFR ~50)
• Losartan provides renoprotection even when proteinuria status is uncertain
• The RENAAL trial demonstrated losartan reduced progression to ESRD by 29% and doubled serum creatinine by 25% in diabetic nephropathy patients 2
• Losartan reduces proteinuria by 34% on average 2

Starting with losartan positions you optimally whether proteinuria is present or not.

Dosing Strategy for Losartan

• Start at 50 mg once daily 2
• Titrate to 100 mg daily if blood pressure goal (<130/80 mmHg per 2025 AHA/ACC guidelines 3) is not achieved after 2-4 weeks
• The FDA label confirms this approach, with proven benefits achieved at these doses 2

Critical monitoring: Check BP, serum creatinine, and potassium within 2-4 weeks of initiation 1. Continue losartan unless creatinine rises >30% within 4 weeks 1.

Second-Line: Add Hydrochlorothiazide

When BP Remains Uncontrolled on Losartan Alone

Add hydrochlorothiazide 12.5 mg daily as the second agent. This combination is supported by:

• FDA-approved combination therapy starting at losartan 50 mg/HCTZ 12.5 mg 2
• The 2025 AHA/ACC guidelines recommend thiazide-like diuretics as part of first-line combination therapy 3
• Superior efficacy data: The losartan/HCTZ combination achieved blood pressure goals in 63.5% of patients versus 37.5% with stepped-care (P=0.008), with significantly better tolerability 4
• Additive renoprotective effects: In CKD patients with proteinuria, losartan/HCTZ reduced proteinuria more than losartan alone, independent of blood pressure reduction 5

At eGFR ~50 mL/min/1.73 m², thiazide diuretics remain effective, though loop diuretics should be considered if eGFR drops below 30 mL/min/1.73 m² 6.

Titration of Combination Therapy

If BP remains uncontrolled:

• Increase to losartan 100 mg/HCTZ 25 mg 2
• This was the target dose in major trials demonstrating cardiovascular and renal benefits

Third-Line: Add Amlodipine

If Two Agents Are Insufficient

Add amlodipine 5 mg daily, which can be increased to 10 mg if needed. This creates the optimal triple therapy combination recommended by guidelines:

• 2025 AHA/ACC guidelines explicitly recommend ACE inhibitor or ARB + CCB + thiazide-like diuretic for resistant hypertension 3
• KDIGO 2021 recommends dihydropyridine CCBs as appropriate add-on therapy 1
• In head-to-head comparison in renally impaired patients, losartan was more effective than amlodipine at reducing both blood pressure and albuminuria 7, supporting losartan as the primary agent with amlodipine as adjunctive therapy

Why Not Metoprolol?

Metoprolol should be reserved as a fourth-line agent in this scenario because:

• Beta-blockers are not part of first-line therapy in the 2025 AHA/ACC guidelines for uncomplicated hypertension 3
• The LIFE study showed losartan was superior to atenolol (a beta-blocker) in reducing cardiovascular events, particularly stroke (25% risk reduction, P=0.001) 2
• Beta-blockers lack the specific renoprotective benefits of RAS inhibitors
• They should be added only if there are specific indications (heart failure with reduced ejection fraction, post-MI, atrial fibrillation rate control) or if the three-drug regimen above fails

Stepwise Algorithm Summary

1. Start losartan 50 mg daily

   • Monitor BP, creatinine, potassium at 2-4 weeks
   • Titrate to 100 mg if BP goal not achieved

2. Add HCTZ 12.5 mg daily if BP remains ≥130/80 mmHg

   • Can increase to HCTZ 25 mg with losartan 100 mg

3. Add amlodipine 5 mg daily if still uncontrolled

   • Can increase to 10 mg

4. Consider metoprolol only as fourth-line or if specific cardiac indications exist

Critical Caveats

Obtain urine albumin-to-creatinine ratio as soon as possible. If proteinuria is confirmed (especially if ≥300 mg/g), this validates the losartan-first strategy and supports maximizing the dose to 100 mg daily 1. The presence of proteinuria strengthens the indication for RAS inhibition (Grade 1B recommendation) 1.

Hyperkalemia management: Don't automatically stop losartan if potassium rises. Use dietary potassium restriction and potassium binders to maintain therapy 1, as the renoprotective benefits are substantial.

Avoid combining losartan with ACE inhibitors or direct renin inhibitors - this is explicitly contraindicated (Grade 1B) 1.